WHO pauses trial of hydroxychloroquine in COVID-19 patients due to safety concerns


  • World
  • Tuesday, 26 May 2020

FILE PHOTO: Laura Ng, who has lupus and had to recently call at least five pharmacies before she could find a place to fill her hydroxychloroquine prescription, is photographed in Seattle, Washington, U.S. March 31, 2020. REUTERS/Lindsey Wasson

GENEVA (Reuters) - The World Health Organization has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.

Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus. The U.S. President has said he was taking the drug to help prevent infection.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In World

Is online shopping bad for the planet?
Haiti police bolster security around palace ahead of transition
Tesla posts Q1 results with declined revenue
Argentina's Milei faces biggest protest yet as students march over budget cuts
2nd LD: Plane crashes into river in Alaska
U.S. crude oil inventories down last week: API
1st LD: Plane crashes into river in Alaska
Urgent: Plane crashes into river in Alaska
Ukraine introduces power supply restrictions to businesses, industry
Feature: Spanish city of Barcelona celebrates day of books and love

Others Also Read